# A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Study · id `cardio:ct-nct02087917` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02087917](<https://clinicaltrials.gov/study/NCT02087917>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02087917

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

## Technical summary

Registry record NCT02087917. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2014-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 376 participants (enrolled count; ClinicalTrials.gov record NCT02087917, source copy `cardio:ctgov-nct02087917-2015-01-06`, retrieved 2026-10-31)
- Start date: 2014-03 (registry gives no type) (ClinicalTrials.gov record NCT02087917, source copy `cardio:ctgov-nct02087917-2015-01-06`, retrieved 2026-10-31)
- Primary completion: 2014-09 (actual) (ClinicalTrials.gov record NCT02087917, source copy `cardio:ctgov-nct02087917-2015-01-06`, retrieved 2026-10-31)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT02087917, source copy `cardio:ctgov-nct02087917-2015-01-06`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT02087917, source copy `cardio:ctgov-nct02087917-2015-01-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02087917-2015-01-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
- Condition: Primary Hypercholesterolemia
- Intervention (Drug): HS-25
- Intervention (Drug): Placebo
- Lead sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Covance
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as a collaborator: Covance (`cardio:org-covance`)

## Provenance

Content hash: ed66e24f783583a0293254d06ad9f6e5f15ea2be4d9f976710accc500edc4841
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
